Back to browse

Endosomal escape cell-penetrating peptides significantly enhance pharmacological effectiveness and CNS activity of systemically administered antisense oligonucleotides

Paper ID

PAPER000067

Year

2021

DOI

10.1016/j.ijpharm.2021.120398

PMID

33640427

Journal

International Journal of Pharmaceutics

Source URL

Experiments

• EXP000251 with HA2 (ASO (PMO))
• EXP000252 with GALA (ASO (PMO))
• EXP000253 with NLS (ASO (PMO))
• EXP000254 with ApoE(141–150) (ASO (PMO))
• EXP000255 with HA2-ApoE(141–150) (ASO (PMO))
• EXP000256 with GALA-ApoE(141–150) (ASO (PMO))
• EXP000257 with NLS-ApoE(141–150) (ASO (PMO))
• EXP000258 with H4-ApoE(141–150) (ASO (PMO))
• EXP000259 with A4-ApoE(141–150) (ASO (PMO))
• EXP000260 with Myr-ApoE(141–150) (ASO (PMO))
• EXP000261 with Myr-HA2-ApoE(141–150) (ASO (PMO))
• EXP000262 with ApoE(133–150) (ASO (PMO))
• EXP000263 with HA2-ApoE(133–150) (ASO (PMO))
• EXP000264 with Myr-ApoE(133–150) (ASO (PMO))
• EXP000265 with Myr-HA2-ApoE(133–150) (ASO (PMO))
• EXP000266 with CLIP6 (ASO (PMO))
• EXP000267 with pVEC (ASO (PMO))
• EXP000268 with Cy5-ApoE(141–150) (ASO (PMO))
• EXP000269 with Cy5-HA2-ApoE(141–150) (ASO (PMO))
• EXP000270 with Cy5-ApoE(133–150) (ASO (PMO))
• EXP000271 with Cy5-HA2-ApoE(133–150) (ASO (PMO))
• EXP000272 with HA2-ApoE(133–150) (ASO (PMO))